© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#drug resistance
Extensive Drug Resistance Has Become Rare Among People With HIV
Why Adherence Is Important
Traffic light with green light illuminated
What Is Drug Resistance?

FDA Approves Rukobia for People With Multidrug-Resistant HIV

The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.

Adherence to HIV Treatment in the U.S. Remains Quite Poor

A recent analysis suggested that only one in four people on antiretroviral treatment take 95% or more of their doses.

Treatment: Fostemsavir Filed

ViiV applies for FDA approval of HIV drug fostemsavir

PrEP Use Tied to Some Drug Resistance in Those Who Contract HIV

In a recent small study, resistance was limited to the emtricitabine component of Truvada and did not seem a major cause for concern.

Treatment: Twice-Yearly Therapy?

Gilead’s HIV capsid inhibitor might need dosing only every six months

Pharmacies Aren’t Doing Their Part to Aid in Opioid Disposal

A recent survey found that pharmacies are insufficiently educating the public about unused opioid and antibiotic disposal.

Trogarzo Bests Highly Resistant HIV

Expanded access study confirms the long-acting monoclonal antibody works well in people with extensive prior treatment.

ViiV Applies for FDA Approval of HIV Drug Fostemsavir

The attachment inhibitor performed well as an adjunct to an optimized antiretroviral regimen among those with multidrug-resistant HIV.

Extensive Drug Resistance is Rare

Researchers attribute the decline in multidrug-resistant virus, which began in 2004, to newer, highly potent antiretrovirals.

Gilead’s HIV Capsid Inhibitor Might Need Dosing Only Every 6 Months

Studies indicate that there is a very low likelihood that people with HIV have preexisting resistance to the medication.

Fostemsavir Can Best Drug-Resistant HIV

The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.

Treatment: Capsid Inhibitor

The investigational, injectable, long-acting antiretroviral is a potential new option for those with multidrug resistance.

Fostemsavir Offers Hope for Those With Few HIV Treatment Options

The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.

Gilead’s HIV Capsid Inhibitor Worked Well in 1st Human Trial

The investigational, injectable, long-acting antiretroviral is a potential new option for those with multidrug resistance.

Biktarvy Suppresses HIV Well in Women and Those With Drug Resistance

Currently, Gilead Sciences’ HIV regimen is not approved to treat drug-resistant virus.

New Combo Could Work as Backup Treatment for Drug-Resistant Gonorrhea

However, because this combo is not as effective as the current standard treatment, the search for new options continues.
Advertisement
Ask POZ
Treatment News